ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1815

Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease

Gary Ho1, Michael Toprover2, Daria Crittenden3, binita Shah4 and Michael Pillinger5, 1New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, 2Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, 3CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, 4New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, 5NYU Grossman School of Medicine, New York, NY

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Cohort Study, gout, Heart disease, prevention

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced by gout patients between flares may further increase CV risk beyond traditional risk factors.

Colchicine has proven efficacy for the secondary prevention of major adverse cardiovascular events (MACE) in all-comers with coronary artery disease (CAD) and has retrospectively been associated with reduced MACE in the general gout population. The objective of this study is to evaluate the association between colchicine use and MACE in gout patients with established CAD.

Methods: This retrospective cohort study followed patients with gout and established CAD within the VA NY Harbor Healthcare System from 2000 to 2009 (preceding the 2012 ACR Gout Treatment Guidelines, which limited colchicine use to acute flares and/or prophylaxis), who did or did not use colchicine (minimum > 30 continuous days prescription). Criteria for the diagnosis of gout included: crystal proven gout; ≥ 6/12 of the 1977 American Rheumatology Association (ARA) Gout Classification Criteria; ≥ 4/12 ARA criteria and a primary care diagnosis of gout; or a rheumatologist diagnosis of gout. Pre-existing CAD was defined as: primary care or cardiologist documentation of CAD; positive cardiac stress test; ≥ 50% stenosis on coronary angiography; prior myocardial infarction (MI); or prior coronary revascularization. The primary outcome was first MACE event, defined as non-fatal MI, coronary artery bypass graft, non-fatal stroke, or all-cause mortality. Pre-specified subgroup analyses assessed associations by percentage of time on colchicine.

Results: Among 1,689 patients with gout, 355 had established CAD (239 colchicine users and 116 nonusers). Colchicine users had higher LDL-cholesterol levels, and a more frequent history of percutaneous coronary intervention and/or MI, potentially indicating more severe baseline coronary disease. On primary analysis, the odds of MACE were not decreased with colchicine use (OR 1.28; 95% CI [0.69-2.35]). However, due to widely varying degrees of colchicine use, colchicine users were next separated into quartiles by percentage of time on colchicine (Figure 1): Quartile 1 (11.4% ± 4.9%), Quartile 2 (31.3% ± 7.4%), Quartile 3 (56.6% ± 7.8%), and Quartile 4 (88.5% ± 9.9%). Patients in Quartile 4 demonstrated significantly lower odds of MACE compared to those in the lowest three quartiles (OR 0.35; 95% CI [0.13-0.93]), along with trends towards similar reductions in subcomponents (Figure 2). Colchicine users also had numerically fewer MACE events during periods of active use compared with periods of lapse (not shown). Kaplan-Meier analysis revealed a difference in cumulative MACE over time, favoring the highest colchicine-use quartile (plog-rank = 0.01) (Figure 3).

Conclusion: Among patients with gout and CAD receiving colchicine, those with the most consistent colchicine use ( > 70% of observation period on colchicine) had lower odds of MACE when compared to less consistent use. These data support the cardiovascular benefit of colchicine in high-risk populations and suggests the need for prospective trials.

Supporting image 1

Mean and standard deviation percentage of time on colchicine within each quartile, Quartiles 1_3, and all subjects.

Supporting image 2

Incidence of first MACE and sub-component events in Quartiles 1_3 versus Quartile 4.

Supporting image 3

Kaplan-Meier survival curves in Quartiles 1_3 and Quartile 4 illustrating the cumulative proportion of patients experiencing a first MACE over time; maximum observation period of 10 years. Patients censored at the end of their respective observation periods are demarcated by a vertical line.


Disclosures: G. Ho, None; M. Toprover, Horizon Pharma; D. Crittenden, CymaBay Therapeutics; b. Shah, Horizons Therapeutic, Terumo medical, Philips Volcano; M. Pillinger, Horizon Therapeutics, Sobi, Fortress Bioscience, Hikma.

To cite this abstract in AMA style:

Ho G, Toprover M, Crittenden D, Shah b, Pillinger M. Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/consistent-colchicine-use-is-associated-with-decreased-major-adverse-cardiovascular-events-in-patients-with-gout-and-established-cardiovascular-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/consistent-colchicine-use-is-associated-with-decreased-major-adverse-cardiovascular-events-in-patients-with-gout-and-established-cardiovascular-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology